Author

F. B. Furnari

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:clinical cohort / trial· 1 Research Focus:clustering· 1

Frequent Co-Authors

S. Miki· 3 shared P. S. Mischel· 2 shared T. Koga· 2 shared A. D. Boyer· 1 shared A. D. Parisian· 1 shared A. Khan· 1 shared A. M. Armando· 1 shared A. Rajapakse· 1 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

S. Miki

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Glioblastoma Mesenchymal Transition and Invasion are Dependent on a NF-κB/BRD2 Chromatin Complex

r. vadla, S. Miki, B. Taylor, D. Kawauchi, B. M. Jones, N. Nathwani, P. Pham, J. Tsang, D. A. Nathanson, F. B. Furnari

This study identifies the PTEN-NF-κB-BRD2 pathway as critical for glioblastoma mesenchymal transition and invasion, suggesting BET-BD2 inhibitors as a therapeutic strategy.

bioRxiv · Jul 3, 2023 · PreprintCancer Biology

Epidermal Growth Factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium

P. Wang, R. Zhou, R. Zhou, L. Yu, L. Zhao, W. Li, J. Lin, A. Rajapakse, C.-H. Lee, F. B. Furnari, A. W. Burgess, J. H. Gunter, G. Liu, K. Ostrikov, D. J. Richard, , E. Thompson

The paper shows EGF enhances TNBC cells' response to CAP-activated medium by activating specific EGFR phospho-tyrosines and increasing ROS levels.

bioRxiv · May 30, 2023Cancer Biology

Targeting Glioblastoma Signaling and Metabolism with A Re-Purposed Brain-Penetrant Drug

J. Bi, A. Khan, J. Tang, S. Wu, W. Zhang, R. C. Gimple, T. Koga, A. M. Armando, S. Miki, H. Yang, B. Prager, E. J. Curtis, D. A. Wainwright, F. B. Furnari, J. N. Rich, , P. S. Mischel

This study identifies fluoxetine as a potential therapy for glioblastoma by inhibiting SMPD1 and enhancing temozolomide efficacy, with real-world evidence suggesting improved survival.

bioRxiv · Mar 16, 2021Cancer Biology

Cancer avatars derived from genetically engineered pluripotent stem cells allow for longitudinal assessment of tumor development

T. Koga, J. A. Benitez, I. A. Chaim, S. Markmiller, A. D. Parisian, R. F. Hevner, K. M. Turner, F. M. Hessenauer, M. D'Antonio, N.-p. D. Nguyen, S. Saberi, J. Ma, S. Miki, A. D. Boyer, J. Ravits, , F. B. Furnari

This paper introduces cancer avatar models using genetically engineered hiPSCs to study tumor development and heterogeneity in glioblastoma.

bioRxiv · Oct 25, 2019Cancer Biology